With increasing cardiac dysfunction, a complex neurohormonal response results in
increasing circulating levels of an array of plasma hormones. Increments in plasma levels of …

Background: Neither profiles nor prognostic value of cardiac N‐terminal proBNP (NT‐
proBNP) have been prospectively evaluated in a sufficient number of patients with severe …

N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is a well‐established biomarker in
heart failure (HF) but controversially discussed as a potential surrogate marker in HF trials …

Normal brain natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) levels are
helpful in excluding chronic heart failure in the ambulatory setting, although they have been …

The long-predicted endocrine function of the heart has been proven by the discovery of atrial
natriuretic peptide (atrial natriuretic factor, A-type natriuretic peptide; ANP) 20 years ago …

Guidelines for the pharmacological treatment of heart failure (HF) are based on results from
large clinical trials demonstrating benefit. State of the art pharmacological management of …

Background: Both BNP (B-type natriuretic peptide) and NT-proBNP (N-terminal pro B-type
natriuretic peptide) are widely used to aid diagnosis, assess the effect of therapy, and predict …

BACKGROUND: NT-proBNP is useful for heart failure (HF) diagnosis and prognosis. We
examined the value of serial NT-proBNP monitoring to predict outcomes in decompensated …

Background: The prognosis of chronic heart failure has improved with modern medical
therapy. However, identifying those patients who fail to respond to such therapy and …

Objectives: This study sought to evaluate the association between changes over time of N-
terminal pro-brain natriuretic peptide (NT-proBNP) expressed in different ways and outcome …